Nuclear hormone receptors function as ligand activated transcription factors. Ligand binding and modification such as acetylation have been reported to regulate nuclear hormone receptors. The orphan receptors, Rev-erbα and Rev-erbβ, are members of the nuclear receptor superfamily and act as transcriptional repressors. In this study, the role of recruitment of co-factors by Rev-erbβ and acetylation of Rev-erbβ in modulating apolipoprotein CIII (apoCIII) transcription were investigated. Rev-erbβ was found to transcriptionally repress apoCIII after binding to the apoCIII promoter. Tip60, a histone acetyl-transferase (HAT), was a novel binding partner for Rev-erbβ and recruited to the apoCIII promoter by Rev-erbβ. Tip60 was able to acetylate Rev-erbβ and relieve the apoCIII repression mediated by Rev-erbβ. This de-repression effect depended on acetylation of Rev-erbβ at its RXKK motif by Tip60. In addition, histone deacetylase 1 (HDAC1) interacted with Rev-erbβ and was recruited to the apoCIII promoter by Rev-erbβ to antagonize Tip60's activity. Taken together, we have provided evidence that Rev-erbβ modulates the apoCIII gene expression by recruiting different transcription co-activator or co-repressor.
Introduction
The family of the nuclear receptors (NRs) consists of transcription factors that regulate many important biological processes [1] . NRs have also been implicated in various diseases such as cancer, diabetes, and osteoporosis [1] . So far, about 50 human NRs have been identified [2] . Approximately 15% of current drugs function through interactions with NRs [3] . The NR family is the third major target for the pharmaceutical industry, following G protein-coupled receptors and kinases [3] . Transcriptional activities of NRs are often regulated by direct ligand binding and formation of a complex with co-regulators [4, 5] . However, regulation of orphan nuclear receptors, whose ligands have not been identified, is poorly understood.
The Rev-erb family is a sub-group of orphan receptors, two members of which have been isolated from mammalian genomes: Rev-erbα, also known as Ear-1 or NR1D1 and Rev-erbβ, also known as RVR, NR1D2 or BD73 [6] . Major differences between the two exist within the hyper-variable A/B and D regions of the proteins. Rev-erb receptors have a broad expression pattern and have been described as negative transcriptional regulators [7] for many targets including Nmyc [8] , Bmal1 [9] , enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase bifunctional enzyme [10] , α-fetoprotein [11] , rat apolipoprotein AI [12] , apoCIII [13] and Rev-erbá [14] . Monomers of Rev-erbα and Rev-erbβ bind to the six-nucleotide core motif PuGGTCA preceded by a 6-bp AT-rich region, referred to as ROREs [15] . The activities of Rev-erb receptors can be modified by co-factors. For example, interaction of Reverbα or Rev-erbβ with a corepressor, N-CoR, enhances transcriptional repression of the orphan receptors [16] . Despite extensive research, however, it is still not clear how the transcriptional repression mediated by Rev-erbβ or Rev-erbα is removed.
Apolipoprotein CIII (ApoCIII) is a major component of triglyceride-rich lipoproteins, including chylomicrons and very low density lipoprotein (VLDL) [17] . It is well established that the synthesis rate of apoCIII is positively correlated with hypertriglyceridemia and over-expression of human apoCIII gene leads to acute hypertriglyceridemia in transgenic mice [18, 19] . Hypertriglyceridemia is an independent risk factor for coronary artery diseases [20] . In addition, triglyceride-rich remnant lipoproteins are positively correlated with progression of atherosclerosis, which remains one of the leading causes of death in the western world [21] . Rev-erbα is able to repress expression of apoCIII by binding to its promoter directly [13] . Our recent research also provided the evidence for the direct binding of Rev-erbβ to the promoter of apoCIII [46] .
In this report, Tip60 was recruited to the apoCIII promoter and consequently relieved the transcriptional repression of apoCIII by Rev-erbβ. This effect of Tip60 was achieved by acetylation of Rev-erbβ on the RXKK motif. The process of acetylation did not affect the binding of Rev-erbβ to the apoCIII promoter. In addition, HDAC1 reversed the effect of Tip60 on Rev-erbβ after recruitment to the apoCIII promoter by Rev-erbβ. Taken together, we have confirmed that transcriptional activity of Rev-erbβ can be regulated by Tip60 and HDAC1 and established a mechanism by which transcriptional repression by orphan nuclear receptors Rev-erbβ is removed.
Materials and methods

Plasmids construction and protein expression
The coding sequence (CDS) of human Rev-erbβ was amplified from human marathon liver cDNA library (Clontech) by PCR and subcloned into pET28a (Novagen), pCMV-HA (Clontech), pCMV-Myc (Clontech), respectively. Reverbβ mut1, Rev-erbβ mut2, Rev-erbβ mut3 and Rev-erbβ mut4 were generated by PCR. The CDS of human Tip60 and HDAC1 were amplified separately from marathon liver cDNA library (Clontech) by PCR and subcloned into pGEX4T-3 (Pharmacia Biotech), pCMV-HA (Clontech) or pCMV-Myc (Clontech) vectors. The Tip60 HAT-defective mutant, Tip60 Q377E/G380E [22] , was generated by PCR and subsequently cloned into pET28a and pCMV vector. The pET28a-Rev-erbβ or pGEX4T-3-Tip60 was expressed in Escherichia coli strain BL21 DE3. Purification of proteins was performed according to the manufacturer's instruction (Novagen).
Yeast two-hybrid screening and mapping the region of Rev-erbβ necessary for binding to Tip60
A yeast two-hybrid screen was performed using the Matchmaker GAL4 Two-hybrid system 3 (Clontech) according to the manufacturer's instruction. Rev-erbβ was used as bait to screen the human fetal liver cDNA library (Clontech). The mating test was used to pick out the specific interaction between bait and prey. Based on the analysis of protein structure in SMART, the result of yeast two-hybrid screening and also references, a series of truncated versions of Rev-erbβ were designed. Rev-erbβΔ1 (100-579aa), Rev-erbβΔ2 (199-579aa), Rev-erbβΔ3(289-579aa), Rev-erbβΔ4(397-579aa), ReverbβΔ5(1-397aa), Rev-erbβΔ6(1-289aa), Rev-erbβΔ7(1-188aa), ReverbβΔ8(1-101aa), and Rev-erbβΔ9(101-188aa) were generated by PCR and subsequently cloned into pGBKT7 vector in-frame with Gal4BD. The yeast two-hybrid system (Clontech) was used to map interacting regions of Rev-erbβ and Tip60.
Luciferase reporter gene assay
The promoter of human apoCIII gene (nt −1408 to +24) was obtained from human genomic DNA by PCR and subcloned into the promoter-less luciferase reporter plasmid pGL3-basic (Promega), generating pGL3-apoCIIIpro. Human hepatoblastoma HepG2 cells were cultured in a basal Eagle medium supplemented with 10% (v/v) fetal calf serum. The cells seeded in 24-well plates at a density of 1 × 10 5 were co-transfected using FuGENE 6 reagent (Roche Molecular Biochemicals) with 100 ng of apoCIII's promoter-driven luciferase expression plasmid pGL3-apoCIII-pro and indicated amount of human Rev-erbβ-expressing plasmid pCMV-HA-Reverbβ as well as 10 ng of a pRL (sea pansy) as an internal control for transfection efficiency. The dosage of transfected plasmids in each well was kept constant by addition of appropriate amounts of the empty vector pCMV-HA. After 3 days, cells were lysed by 200 μl Promega lysis buffer for 10 min at room temperature. Firefly and Renilla luciferase activities were measured using a Dual-Luciferase® Reporter Assay Kit (Promega) on a Lumistar luminometer (BMG Lab Technologies). Firefly luciferase activity values were divided by Renilla luciferase activity values to obtain normalized luciferase activities. To facilitate comparisons within a given experiment, activity data were presented as relative luciferase activities. The final relative activity was calculated from three independent experiments performed in triplicate.
Chromatin immunoprecipitation
The 293T cells were co-transfected with 0.5 μg of the plasmid pGL3-apoCIII-pro and 1 μg of either pCMV-HA-Rev-erbβ or empty vector pCMV-HA. HepG2 cells were co-transfected with 1 μg of pCMV-HA-Rev-erbβ and pCMV-Myc-Tip60 or pCMV-Myc-HDAC1. After incubation, a chromatin immunoprecipitation (ChIP) assay and PCR were performed as described [23] . Purified immuno-enriched and input genomic DNA samples were also used for real-time sequence-specific PCR reactions.
GST pull-down assay
GST-Tip60 and GST-HDAC1 fusion proteins were separately expressed in bacteria and purified on glutathione-Sepharose (Pharmacia) as specified by the manufacturer. The 6His-tagged Rev-erbβ protein was expressed in bacteria and purified on Ni-nitrilotriacetic acid agarose (Qiagen). GST pull-down assays were performed as described [24] .
Co-Immunoprecipitation assay
HepG2 cells were co-transfected with pCMV-HA-Rev-erbβ and pCMVMyc-Tip60 or pCMV-Myc-HDAC1. At 48 h of post-transfection, cells were collected and lysed in the TPER Lysis Buffer (Pierce). After analyzing the expression of HA-Rev-erbβ, Myc-Tip60 or Myc-HDAC1 by western blotting using anti-HA or anti-Myc antibody, the co-immunoprecipitation (CO-IP) assay was carried out as described [24] .
Immunofluorescence and protein subcellular localization analysis
Immunofluorescence localization was performed as described [25] . After fixation and permeabilization, HepG2 cells were incubated with anti-Rev-erbβ or anti-Tip60 primary antibody for 1 h at room temperature. After washing, the cells were incubated with the secondary antibody (green and red FITC conjugated) at a dilution of 1:50 for 1 h in a humidified chamber at room temperature. The cells were washed by PBS and stained with 1 μg/ml of 4′, 6′-diamidino-2-phenylindole (DAPI) to visualize nuclei and were then observed and captured under the Olympus IX71 laser microscope.
Acetylation assays in vitro
Acetylation assays in vitro were performed as described [26] 
Immunoprecipitation and acetyltransferase assay
HepG2 cells were co-transfected with 1 μg of pCMV-HA-Rev-erbβ and 1 μg of either pCMV-Myc-Tip60 or empty pCMV for control per 35-mm dish. Anti-HA antibody was used to immunoprecipitate Rev-erbβ complex. After washing 3 times with the HAT assay buffer (10% glycerol, 2 mM MgCl 2 , 0.5 mM EDTA, 15 μM TSA, 0.5 mM PMSF and 1 mM DTT), Rev-erbβ complex was incubated with 5 mM [ 3 H]acetyl-CoA in 200 μl HAT assay buffer. HAT assays were performed as described [26] . The data were calculated from three independent experiments performed in triplicate and presented as means ± S.D. Autoradiograph was generated by Fujifilm FLA-5100 Storage Phosphor Imager.
Quantitative real-time PCR
Total RNA was prepared using an RNeasy kit (Qiagen). cDNA was synthesized from RNA treated with DNase followed by reverse transcription reaction (Invitrogen) according to manufacturer's instructions. mRNA transcripts were quantified by SYBR GREEN PCR kit (Applied biosystems), using a Prism 7900 thermal cycler and sequence detector (Applied Biosynthesis). Forward primer (5′-GGGTACTCCTTGTTGTTGCCCT-3′) and reverse primer (5′-CCACGGCTCTGAAGTTGGTCTGAC-3′) for apoCIII were designed to ensure specific amplification of a 252-bp fragment of apoCIII. After amplification, a dissociation curve was performed on all PCR products to ensure that specific PCR products were generated. The real-time PCR results were analyzed using the sequence detection system software V1.1 (Applied Biosystems). The apoCIII expression levels were calculated using the comparative CT method and normalized to expression level of β-actin that was amplified by forward primer (5′ATGTCTCGCTCCGTGGCCTTAG 3′) and reverse primer (5′GCTTACATGT CTCGATCCCA C 3′). All of the transfection experiments were performed at least three times and each cDNA sample was tested in triplicate. The data are expressed as the means ± S.D.
Results
Rev-erbβ binds to the promoter of human apoCIII gene and represses its activity
Rev-erbα has been reported to bind to the promoter of human apoCIII and regulate its activity [13] . We recently also showed that Rev-erbβ could directly bind to the promoter of apoCIII (Wang et al., unpublished) . To confirm this observation, both wild type and mutant of the apoCIII promoter were used in this study. The promoter region of apoCIII from nt − 1408 to +24 was amplified by PCR and cloned in front of the firefly luciferase reporter gene. pCMV-HA-Rev-erbβ and pGL3-apoCIII-pro or pGL3-apoCIII-pro-mut were co-transfected into 293T cells and incubated for 2 days followed by a ChIP assay. As shown in Fig. 1A , Rev-erbβ was capable of binding to the wild promoter of human apoCIII, but failed to bind pGL3-apoCIII-pro-mut which was mutated at the half-site of the ROREs [13] . Moreover, Rev-erbβ dramatically repressed expression of luciferase, when pGL3-apoCIII-pro was cotransfected ( Fig. 1B) . The magnitude of repression was dependent upon the amount of transfected Rev-erbβ. Conversely, the mutant promoter of human apoCIII was not repressed by Rev-erbβ. These results indicate that the interaction between Rev-erbβ and the apoCIII promoter was specific and functional.
Rev-erbβ interacts with Tip60 in vitro and in vivo
To explore how Rev-erbβ was regulated, co-factors were identified using a yeast two-hybrid screening and Tip60 was found to be one of Rev-erbβ-interacting proteins. Tip60 was originally recognized as a cellular acetyltransferase protein that interacts with HIV-1 Tat [27] . Alternative splicing results in the expression of at least three splice variants, Tip60 isoform 1 [28] , Tip60 isoform 2 (Tip60α) [27] and Tip60 isoform 3 (Tip60β, PLA2 interacting protein, PLIP) [29] . Tip60 isoforms 1 and 3 are expressed at relatively low levels in a broad variety of tissues and cells and exhibit cell type specific functions [30] . The best-characterized splice variant is isoform 2, which is also the isoform investigated in this study. The interaction between Tip60 and Rev-erbβ was further verified by a GST pull-down assay in vitro and a CO-IP assay in vivo. As shown in Fig. 2A , bacterially expressed GSTTip60, when conjugated to glutathione-Sepharose beads, efficiently and specifically pulled down 6His-tagged Rev- erbβ. Conversely, GST alone did not. The CO-IP assay was performed using HepG2 cell lysates containing over-expressed tagged proteins of HA-Rev-erbβ and Myc-Tip60. As shown in Fig. 2B , anti-Myc antibody could immunoprecipitate HAtagged Rev-erbβ. Furthermore, the interaction was confirmed by endogenous CO-IP. As shown in Fig. 2C , anti-Tip60 antibody could immunoprecipitate HA-tagged Rev-erbβ, and anti-Rev-erbβ antibody could also immunoprecipitate Myctagged Tip60 (Fig. 2D ). Without transfection of any plasmid, anti-Tip60 antibody could also immunoprecipitate endogenous Rev-erbβ (Fig. 2E) . Consistent with the yeast two hybrid screening result, the GST pull-down and endogenous CO-IP assays confirmed that Tip60 could bind to Rev-erbβ specifically.
N-terminal of Rev-erbβ is required for interacting with Tip60
To identify the region of Rev-erbβ essential for the interaction with Tip60, serial deletion assays were performed using the yeast two-hybrid method and the pull-down assay. Rev-erbβ consists of five regions, A/B, C, D, and E. The highly conserved region C is responsible for DNA binding and region E is a putative ligand binding domain and mediates co-repressor recruitment [16] . N-and C-terminal deletion constructs of Reverbβ (Fig. 3A) were fused in-frame to GaL4 BD and tested for their abilities to bind Tip60 by checking activation of reporter genes Ade2, His3, and LacZ. The result showed that Tip60 bound specifically to N-terminus of Rev-erbβ (Rev-erbβΔ7) rather than C-terminal putative ligand binding domain. To test the strength of interactions, a semi-quantitative test of relative-β-galactosidase activity was carried out (Fig. 3B) . The Reverbβ Δ5 1-397 had same strength of interaction as intact Reverbβ did. Rev-erbβ Δ7 1-188 containing A/B region and DNA binding domain (region C) revealed the strongest interaction, suggesting that the A/B region and the DNA binding domain (DBD) of Rev-erbβ were necessary for the interaction with Tip60. Lengthening of Δ7 1-188 reduced the interaction. The interaction between Tip60 and the serial truncated fragments of Rev-erbβ was further verified by a GST pull-down in vitro assay (Fig. 3C) .
Subcellular co-localization of Rev-erbβ and Tip60
To determine whether the interaction between Tip60 and Rev-erbβ might be of physiological relevance in mammalian cells, subcellular localization and distribution of Tip60 and Rev-erbβ in HepG2 cells were assessed using laser microscopy. Distribution of endogenous Tip60 and Rev-erbβ was identified by immunofluorescence labeling using antiTip60 and anti-Rev-erbβ antibodies, respectively. As shown in Fig. 4A and B, Rev-erbβ and Tip60 were localized in nucleus and exhibited a punctate distribution. Co-localization of endogenous Rev-erbβ and Tip60 in the nucleus was also detected (Fig. 4C) , implying that the interaction between these two proteins may have physiological significance.
Rev-erbβ is acetylated by Tip60
Considering that Tip60 possesses acetyl-transferase activity, we next sought to determine whether Tip60 could acetylate Rev-erbβ. The amino acid sequence of the Rev-erbβ was first screened for potential acetylation sites. KxKK and RxKK have been considered as conserved acetylation motifs for acetylation of non-histone proteins [31, 32] . Rev-erbβ does contain the RxKK motif that exists in ER as the acetylation motif [26] and is also homologous to the acetylation motif KxKK in p53 [23] and AR [22] . This motif is located at residues 159-162 within the zinc finger DNA-binding domain of Rev-erbβ. It is highly conserved from worm to human (Fig. 5A) . Next, whether Tip60 could acetylate recombinant Rev-erbβ was assessed in vitro by comparing the abilities of wild-type Tip60 and a HATdefective Tip60 mutant (Tip60 Q377E/G380E ) [22] to acetylate Rev-erbβ. As shown in Fig. 5B , the purified recombinant 6His-tagged Rev-erbβ was acetylated by purified wild-type Tip60 but not by Tip60 Q377E/G380E . Thirdly, acetylation of Rev-erbβ by Tip60 was analyzed in HepG2 cells by immunoprecipitation followed by an acetyltransferase assay. HepG2 cells were transiently transfected with wild-type pCMV-HA-Rev-erbβ and either pCMV-Myc-Tip60 or empty vector. After 2 days of incubation, cells were lysed and anti-HA antibody and protein A/G beads were added, followed by 1 h incubation with [
3 H] acetyl-CoA. The level of Rev-erbβ acetylation was determined by measuring [ 3 H] acetyl incorporation into Rev-erbβ protein using liquid scintillation counting and autoradiography. As shown in Fig. 5C , Tip60 acetylated Rev-erbβ in HepG2 cells but did not acetylate HA tag.
To further confirm the importance of RxKK motif and neighboring regions in Rev-erbβ acetylation, seven lysine residues near or in RxKK motif in wild type Rev-erbβ were mutated to alanines to create Rev-erbβ mutants mut1-4 (Fig. 5A) . The interaction intensities between Rev-erbβ mutants and Tip60 were assessed by a relative-β-galactosidase activity assay. These point mutations did not affect the binding of Tip60 to Rev-erbβ (Fig. 5D) . Equal amounts of Rev-erbβ and its mutants were also used in the HAT assay with recombinant GST-Tip60 (Fig. 5B) . Comparing with wild Rev-erbβ protein, acetylation ratios of Rev-erbβ mut1, mut2 and mut3 were all reduced by about 50%, suggestive of K 161/162 as the key residues for acetylation of Rev-erbβ. The acetylation ratio of the mut4 was about 10% lower than those in mut1-3, suggesting that K 181 K 184 might affect acetylation in vitro. To further determine the effect of conserved lysines K 161/162 of Rev-erbβ on the acetylation in vivo, wild type Rev-erbβ and mut1 were transfected into HepG2, and western blotting was performed to detect Rev-erbβ expression. Similar amounts of wild type and mutant Rev-erbβ were expressed by transfecting same amounts of plasmids and confirmed by western blotting (data not shown). The wild type and mutant Rev-erbβ were immunoprecipitated from transfected cells by using anti-HA antibody and incubated with [ 3 H] acetyl-CoA. Equal amounts of wild type and mutant Rev-erbβ were used in the HAT assay. The acetylation ratio of the Rev-erbβ mut1 was 70% lower than the wild Rev-erbβ protein in HepG2 cells (Fig. 5C ). In addition, acetylated mutant was not detectable by autoradiography, presumably due to its lower sensitivity comparing with liquid scintillation counting (Fig. 5C ). These results demonstrate that the residues K 161/162 of Rev-erbβ were the dominant acetylation sites for Tip60.
Tip60 relieves Rev-erbβ mediated inhibition of apoCIII expression by acetylating Rev-erbβ
In order to explore the potential physiological function of the interaction between Rev-erbβ and Tip60, HepG2 cells were first transiently co-transfected with pCMV-HA-Rev-erbβ (or pCMV-HA-Rev-erbβ Δ1 or Δ5) and pGL3-apoCIII-pro together with either Myc-Tip60 or empty vector. Relative luciferase activity was used as an indicator for functionality of the interaction between Rev-erbβ and Tip60. As shown in Fig.  6A , Rev-erbβ inhibited expression of the reporter gene by approximately 60%. This inhibition was removed by Tip60. Although Rev-erbβΔ1 inhibited the expression just like Reverbβ, its inhibition was not removed by Tip60, due to the fact that Tip60 could not interact with Rev-erbβΔ1. Due to the absence of E region (LBD), Rev-erbβΔ5 did not inhibit the reporter gene expression. The result from co-transfection of Tip60 and Rev-erbβΔ5 was same as the Rev-erbβΔ5 alone, suggesting that Tip60 might be not involved in histone modification upon the apoCIII promoter. To be more physiologically relevant, HepG2 cells, expressing endogenous ApoC-III, were transiently transfected with Myc-Tip60 and/or HARev-erbβ (or HA-Rev-erbβΔ1) and the relative mRNA level of apoCIII was measured by real-time PCR. As shown in Fig. 6B , over-expression of Rev-erbβ repressed expression of apoCIII by about 30% and the repression was relieved by overexpressed Tip60. However, in the absence of A/B region (ReverbβΔ1), Tip60 could not regulate the transcriptional activity of Rev-erbβΔ1. These results prove that Tip60-mediated regulation of apoCIII gene depended on the interaction with Rev-erbβ.
Tip60 was capable of acetylating Rev-erbβ, as seen in Fig. 5 . The question remained whether acetylation was involved in Tip60-mediated relieve of Rev-erbβ inhibition of apoCIII. To test this, both luciferase reporter system and expression of endogenous apoCIII by real-time PCR were used for the cells transfected with pCMV-Myc-Tip60 (or pCMV-Myc-Tip60 mutant) and either pCMV-HA-Rev-erbβ or pCMV-HA-Reverbβ mut1 (Fig. 6C and D) . Both Rev-erbβ and Rev-erbβ mut1 inhibited activity of the apoCIII promoter, by approximately 60% based on the luciferase activities and by approximately 30% based on endogenous apoCIII expression, respectively. Tip60 relieved Rev-erbβ-mediated repression, but not Reverbβ mut1-mediated repression, due to less acetylation in the mutant as seen in Fig. 5 . At the same time, wild-type Tip60 and a HAT-defective mutant Tip60 were also compared for their abilities to remove Rev-erbβ-mediated inhibition. HepG2 cells were transfected with HA-Rev-erbβ and either Myc-Tip60 or HAT-defective Tip60 (Myc-Tip60 Q377E/G380E mutant). Unlike wild type Tip60, Tip60 Q377E/G380E mutant without the HAT activity could not remove Rev-erbβ-mediated inhibition ( Fig. 6C and D) . To further confirm that acetylation of Rev-erb was involved in removal of the inhibition, a Rev-erbβ mutant (K161Q/K162Q) mimicking acetylation was used in the assay. As shown in the bar 7 of Fig. 6C and D, Rev-erbβ K161Q/ K162Q mutant lost its transcription repression to apoCIII promoter. These results strongly support the notion that sufficient acetylation of Rev-erbβ by Tip60 was essential to regulate Rev-erbβ function.
Rev-erbβ interacts with HDAC1 in vitro and in vivo
The acetylation regulates the transcriptional activity of Reverbβ. Next, we sought to determine the effect of deacetylation. The histone deacetylases, HDACs, are reported to downregulate the transcriptional activity of numerous transcription factors including p53 [23] and AR [22] . We thereby wondered the possibility of a role for HDACs in Rev-erbβ functions. TSA, a specific inhibitor of histone deacetylase, was used to test the effect of deacetylation. When HepG2 cells were stimulated by different concentration TSA, apoCIII mRNA level was significantly enhanced (up to about 8-fold at 200 ng/ml of TSA) (data not shown), indicating that the deacetylation is probably involved in regulation of transcriptional activity of Rev-erbβ. To identify whether HDACs involved in Rev-erbβ regulation, HDAC1-8 were screened for interaction with Reverbβ in the yeast two-hybrid system. HDAC1 were found to interact with Rev-erbβ. The interaction between Rev-erbβ and HDAC1 was confirmed by GST pull-down in vitro (Fig. 7A ) and in vivo CO-IP assay in HepG2 cells transfected with pCMV-Myc-HDAC1 (Fig. 7B) . To map the region of Rev-erbβ required for the interaction with HDAC1, serial truncated fragments of Rev-erbβ (Fig. 3A) were expressed in E. coli, respectively, and analyzed for interaction with HDAC1 by using the pull-down assay. As shown in Fig. 7C , the putative LBD (Rev-erbβΔ4) was required for Rev-erbβ to bind to HDAC1.
Rev-erbβ recruits Tip60 and HDAC1 to the promoter of apoCIII
Since Rev-erbβ interacted with both Tip60 and HDAC1 cofactors as well as the target apoCIII promoter, a logical question was whether Tip60 and HDAC1 were associated with the apoCIII promoter together. To answer this question, a ChIP analysis was performed. In the absence of transfected pCMV-HA-Rev-erbβ, relatively little apoCIII promoter DNA was amplified when anti-Rev-erbβ antibody was used. No amplified apoCIII promoter DNA was detectable using anti-Myc when cells were transfected with Myc-Tip60 or Myc-HDAC1 (Fig.  8A) . After transfection of pCMV-HA-Rev-erbβ, amplification of apoCIII promoter DNA could be detected when anti-Reverbβ or anti-Myc (for Myc-Tip60 and Myc-HDAC1) was used (Fig. 8A) . These results indicate that Rev-erbβ recruited Tip60 and HDAC1 to the apoCIII promoter.
Next, the possible effect of Tip60 and HDAC1 on the binding capacity of Rev-erbβ to the apoCIII promoter was investigated. A ChIP analysis using anti-Rev-erbβ antibody was performed in HepG2 cells transfected with HA-Rev-erbβ alone or cotransfected with Myc-Tip60 or Myc-HDAC1. The binding capacity of Rev-erbβ to apoCIII promoter was assessed by quantitative PCR for ChIP DNA. As shown in Fig. 8B , Tip60 and HDAC1 did not affect Rev-erbβ binding to the apoCIII promoter. These results prove that Rev-erbβ remained on the apoCIII promoter after recruitment of Tip60 and HDAC1.
HDAC1 abrogates the effects of Tip60
Considering that acetylase Tip60 and deacetylase HDAC1 function oppositely upon transcriptional regulation, we wondered whether variation in the relative levels of these proteins could influence the activity of Rev-erbβ. HepG2 cells were cotransfected with increasing amounts of pCMV-Myc-HDAC1 and the same amount of pCMV-myc-Tip60 (1 μg) and pCMV-HA-Rev-erbβ (1 μg). Co-transfection of 150 ng of pCMVMyc-HDAC1 only partially counteracted the effects of Tip60, while co-transfection of 300 and 500 ng of pCMV-Myc-HDAC1 completely abolished the effects of Tip60 (Fig. 9) , implying that dynamically recruiting different coregulators is an important mechanism for regulating Rev-erbβ transcriptional activity.
Discussion
One important finding from this study was the revelation that Rev-erbβ could be acetylated by Tip60. Direct co-activator mediated acetylation of nuclear receptors has emerged as a major determinant in regulating transcriptional activity [33] , akin to the role of phosphorylation in signal transduction cascades. Acetylation has been reported for several nuclear hormone receptors, including androgen receptor (AR) [22] , estrogen receptor (ER) [26] and thyroid hormone receptor (TR) [33] . Here we report that Rev-erbβ represents an orphan nuclear hormone receptor that can be modified by acetylation.
The regions involved in acetylation of Rev-erbβ on both Rev-erbβ and Tip60 were also revealed. Like ER [26] and p53 [34] , Rev-erbβ contains conserved acetylation motif RxKK and was acetylated on this motif. This acetylation motif is also homologous to the acetylation motif KxKK in p53 [23, 34] , AR [22] and GATA [35] . Both Rev-erbβ and AR acetylation motifs are located immediately carboxyl-terminal to the zinc finger DNA-binding domain [22] , while GATA-1 acetylation motif is immediately amino-terminal to its zinc finger DNAbinding domain [35] . Considering that the motif RxKK is next to the DNA binding domain, modification of RxKK may change the charges of DBD. Potentially, acetylation on the lysines neutralizes its positive charge and increases the hydrophobicity of Rev-erbβ, which may reduce the affinity of DBD to DNA. However, three-dimensional modeling of Rev-erbβ-DNA complex by dock 6.0 suggests the distance between RxKK motif and DNA is too far to affect the affinity of Rev-erbβ to DNA (data not shown). Consistent with the modeling analysis result, we observed that Tip60 did not affect Rev-erbβ binding to the apoCIII promoter (Fig. 8B) . Nevertheless, acetylation of Rev-erbβ by Tip60 regulated the transcriptional activity of the apoCIII promoter. Similar results have been reported by Barlev et al., who observed that acetylation of p53 did not change the DNA binding affinity but promoted co-activator recruitment [23] . In addition, Fu et al. demonstrated acetylation of AR enhanced the binding of coactivator and reduced the binding of co-repressor [31] . It is tempting to assume that acetylation of Rev-erbβ by Tip60 removes co-repressors located on the LBD domain. However, the possibility that acetylation of Rev-erbβ by Tip60 enhances the binding of co-activators and reduce the binding of corepressors has not been fully explored in this study. Alternatively, Tip60 could stimulate apoCIII transcription through histone acetylation and alteration of the chromatin structure. It is well accepted that Tip60 functions in chromatin remodeling by acetylating histones [36, 37] . However, the fact that similar results were obtained in the luciferase reporter system and in the cells containing endogenous apoCIII after transfection of pCMV-myc-Tip60 and pCMV-HA-Rev-erbβ mut1 ( Fig. 6C and D) did not support the notion that Tip60 stimulates apoCIII transcription through chromatin remodeling by acetylating histones. The balance between co-activators and co-repressors will influence the effect of Rev-erbβ on apoCIII, as supported by results from Rev-erbβΔ5 in comparison with intact Rev-erbβ. Rev-erbβΔ5 has been constructed by removal of the LBD domain from Rev-erbβ and such a change could lead to removal of co-repressors such as HDAC1 (Fig. 7C) .
HDAC1 was found to interact with Rev-erbβ directly and reversed the effect of Tip60 on Rev-erbβ in this study. Furthermore, histone deacetylase inhibitor TSA significantly up-regulated expression of endogenous apoCIII (data not shown), suggesting that deacetylation is involved in regulating transcriptional activity of Rev-erbβ. While acetylation has been linked to increasing transcriptional activity of targeted transcription factors, deacetylation has been implicated as a mechanism of transcription factor down-regulation [38] . HDACs play key roles in the regulation of gene activity [39] by deacetylating nucleosome histones as well as transcription factors, such as p53 [40] and AR [22] . The demonstration that increasing amounts of HDAC1 counteracted the de-repression mediated by Tip60 (Fig. 8) indicated that deacetylation by HDAC1 was potentially involved in the transcriptional regulation of Rev-erbβ upon apoCIII. However, the exact role of HDAC1 in the transcriptional activity of Rev-erbβ remains to be further investigated.
In addition to the new finding from this study that Tip60 and HDAC1 were co-factors for Rev-erbβ, our previous study also indicated that ZNHIT-1 was a co-factor for Rev-erbβ (Wang et al., unpublished) . With more research, the list for Rev-erbβ co-factors will certainly become longer. The quest for understanding the complex interplay among these factors remains a challenge for future studies. It is quite possible that a trimeric complex of Tip60, HDAC1 and Rev-erbβ exists. This postulation is based on following observations. First, Tip60 and HDAC1 bound to the N-terminal (Fig. 3 ) and C-terminal (Fig.  7C) of Rev-erbβ, respectively. Second, Rev-erbβ recruited both Tip60 and HDAC1 to the apoCIII promoter (Fig. 8A) . Third, neither Tip60 nor HDAC1 affected Rev-erbβ binding to the apoCIII promoter (Fig. 8B) . Considering their opposite functions, the presence of an acetylase and a deacetylase upon the same promoter was intriguing. Nevertheless, co-binding of a coactivator and a corepressor to other nuclear receptors has been observed before, including AR [22] , ER and RAR [41] . Antagonistically functioning proteins do exist within same complex and this may finely tune the transcriptional response. The binding of HADC1 and Tip60 to Rev-erbβ is expected to be a dynamic process to keep the transcription of ApoCIII to meet the physiological requirement. Studies on how physiological and pathological conditions affect the balance between corepressors and coactivators will certainly lead to better understanding of physiological functions of Rev-erbβ.
Transcriptional regulation of ApoCIII by Rev-erbβ is still elusive and might be through following postulated routes.
Firstly, Rev-erbβ is an orphan nuclear receptor. However, it does not mean that no potential ligand could bind Rev-erbβ. E75, a drosophila orthologue of human Rev-erb, is tightly bound by heme and NO [42] , suggesting that there might be some unidentified ligands, which could bind Rev-erbβ and regulate its activity. Similar to 'classical' NRs, binding of unidentified "ligands" to orphan nuclear receptors induce a conformational change of the receptor and recruits or excludes co-regulators. Secondly, some ligand-dependent nuclear hormone receptors bind to the human apoCIII promoter and may affect Rev-erbβ activity. In addition to two ROREs (Fig. 1A , nt −82/−18) that mediate Rev-erbβ binding, there are other hormone response elements (HRE) on the apoCIII promoter [43] . These HRE could be occupied by other ligand-dependent receptor such as the retinoid X receptor (RXR) and peroxisome proliferatoractivated receptor (PPAR)-alpha [13, 43] . These ligand-dependent receptors modulate the apoCIII transcription through recruiting gigantic complexes, which might affect posttranslational modifications of neighboring Rev-erbβ and thus its interactions with coactivators and corepressors. Thirdly, there is increasing evidence that the phosphorylation status of transcription factors might affect not only recruitment of different coregulators but also other posttranslational modifications, such as acetylation [44] . For example, phosphorylation of ER increases transcriptional activity and has been implicated in preventing acetylation of ER [45] . There are many potential phosphorylation sites in Rev-erbβ. However, there is no experimental evidence so far for phosphorylation of Rev-erbβ.
In all, our data have provided a novel insight into the role of acetylation in regulating Rev-erbβ-mediated transcription inhibition of apoCIII and the interplay between HDAC1 and Tip60 proteins in Rev-erbβ function. We have provided evidence that the recruitment of different coregulators is an important mechanism for regulating Rev-erbβ transcriptional activity.
